Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Head & Neck 1

Conditions

Glioblastoma 2Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1Glioma 1Carcinoma, Squamous Cell 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Has results × Re-Irradiation × Clear all
NCT01743950 2026-03-25

A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

University of Wisconsin, Madison

Phase 2 Terminated
49 enrolled 19 charts
CNS

Glioblastoma, Glioma

NCT02289209 2025-03-06

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

University of Pittsburgh

Phase 2 Completed
48 enrolled 18 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03661723 2024-09-19

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Dana-Farber Cancer Institute

Phase 2 Completed
60 enrolled 23 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡